Remove 2020 Remove Food and Drug Administration Remove Healthcare Remove Patients
article thumbnail

Disruption in healthcare is coming

World of DTC Marketing

America’s profit-riddled healthcare-industrial complex consumes 17% of GDP, equivalent to $3.6trn a year. However, changes are slowly being implemented that could lower healthcare costs. Healthcare is ripe for disruption, but any attempt to disrupt our state of healthcare has been met with pushback and challenges.

article thumbnail

What do future healthcare CEOs look like?

World of DTC Marketing

million compensation package in 2020, a slight increase from his $19.6 Pfizer CEO Bourla’s Pay Climbed 17% to $21 Million in 2020 and Gilead Sciences CEO Daniel O’Day earned a $19 million take home. American healthcare is in trouble. Highest-paid CEOs in 2019: Who made the list from healthcare. This has to end.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Navigating the Regulatory Environment of Pharmaceutical Marketing: Balancing Patient Safety and Industry Innovation

Pharma Marketing Network

Pharmaceutical marketing is a critical aspect of the industry, as it helps in spreading awareness about the benefits and potential side effects of different drugs. However, pharmaceutical marketing is also regulated by several agencies to ensure that patients are not exposed to false or misleading information.

Safety 52
article thumbnail

The current pharma business model is unsustainable

World of DTC Marketing

In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. They relied so much on a new drug that they tried to market a product with bad science behind it. The pharma industry is a giant behemoth that needs new drugs to survive and grow.

Pharma 210
article thumbnail

US FDA accepts Accord BioPharma’s BLA for HLX02 to treat cancer

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has accepted Accord BioPharma’s Biologics Licence Application (BLA) for HLX02 (a proposed trastuzumab biosimilar) to treat HER2 cancer types. Biosimilars are key to making healthcare more affordable and accessible.

article thumbnail

European Commission revokes marketing authorisation for Novartis’ crizanlizumab

European Pharmaceutical Review

Crizanlizumab is a once-a-month, humanised monoclonal antibody infusion, indicated for the prevention of recurrent vaso‑occlusive crises (pain crises) in sickle cell disease patients aged 16 years and above. Adakveo (crizanlizumab) received conditional authorisation by the EC in October 2020.

article thumbnail

MHRA, NHS England make available new prostate cancer treatment

pharmaphorum

Based on results from 1,305 patients who participated in the ARASENS randomised, phase 3, multi-centre, double-blind, placebo-controlled clinical trial, the approval was given after the study showed that the combination treatment led to a statistically significant 32.5% It is coordinated by the US Food and Drug Administration (FDA).